The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback